ARS Pharmaceuticals (SPRY) Operating Margin (2022 - 2026)

ARS Pharmaceuticals has reported Operating Margin for 5 years, with the latest figure at 265.18% in Q1 2026.

• Quarterly Operating Margin rose 20111.0% year-over-year to 265.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 204.49% (down 17662.0% YoY) and the FY2025 annual result came in at 212.92%, down 20947.0% from the prior year.
• Operating Margin retreated to 265.18% in Q1 2026 per SPRY's latest filing, from 147.63% in the prior quarter.
• Over five years, Operating Margin peaked at 54.51% in Q4 2024 and troughed at 206030.0% in Q2 2023.
• A 5-year average of 23919.37% and a median of 1051.64% in 2024 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2023 and 2024: Operating Margin plunged 20466276 bps in 2023, then surged 20296200 bps in 2024.
• Over 5 years, Operating Margin stood at 3507.94% in 2022, then slumped by 5773 bps to 206030.0% in 2023, then soared by 100 bps to 54.51% in 2024, then slumped by 371 bps to 147.63% in 2025, then slumped by 80 bps to 265.18% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 265.18%, 147.63%, and 163.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.